A Multi-mode Thermophysical Immunotherapy Study for Breast Cancer Liver Metastases

This is a single-center, parallel-controlled clinical study designed to evaluate the safety, efficacy and impact on systemic anti-tumor immunity of a multi-mode integrated ablation system for the treatment of breast cancer liver metastases.

Trial Details

NCT ID
NCT06567353
Phase
NA
Sponsor
Ruijin Hospital
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Multi-mode tumor treatment system
  • Radiofrequency ablation therapeutic apparatus
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Age 18-75 years, female gender;
  • Pathologically confirmed breast cancer liver metastases, in patients who are unable to tolerate or refuse surgical resection;
  • The number of lesions ≤ 3, with any single lesion diameter ≤ 4cm;
  • At least an interval of 1 month since the last local treatment;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →